Patents Assigned to Annexon, Inc.
  • Anti-complement factor C1q antibodies and uses thereof
    Patent number: 12534522
    Abstract: The present invention provides anti-C1q antibodies and methods of using the same.
    Type: Grant
    Filed: February 16, 2023
    Date of Patent: January 27, 2026
    Assignee: Annexon, Inc.
    Inventors: Arnon Rosenthal, Michael Leviten
  • Inhibitors of complement factors and uses thereof
    Patent number: 12522619
    Abstract: Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.
    Type: Grant
    Filed: January 17, 2023
    Date of Patent: January 13, 2026
    Assignee: Annexon, Inc.
    Inventors: Dean R. Artis, Colin P. Leslie, Luca B. Mileo, Claudia Beato, Federico Sorana, Bruno Di Guglielmo, Chiara Padroni, Federica Faroldi
  • Inhibitors of complement factors and uses thereof
    Patent number: 12509474
    Abstract: Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.
    Type: Grant
    Filed: October 4, 2023
    Date of Patent: December 30, 2025
    Assignee: Annexon, Inc.
    Inventors: Dean R. Artis, Colin P. Leslie, Luca B. Mileo, Claudia Beato, Federico Sorana, Bruno Di Guglielmo, Chiara Padroni
  • Anti-complement factor C1q antibodies with single binding arms and uses thereof
    Patent number: 12486322
    Abstract: The present disclosure relates generally to antibodies with a single antigen-binding arm comprising a single antigen-binding arm and an Fc region such as a single-arm antibodies. The present disclosure also relates generally to the use of such antibodies such as treating a disease associated with complement activation.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: December 2, 2025
    Assignee: Annexon, Inc.
    Inventors: Ted Yednock, Sethu Sankaranarayanan
  • Anti-complement factor C1q Fab fragments and uses thereof
    Patent number: 11999779
    Abstract: The present disclosure relates generally to anti-C1q antibody Fab fragments and methods of using the same.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: June 4, 2024
    Assignee: Annexon, Inc.
    Inventors: Ted Yednock, Sethu Sankaranarayanan, Michael Leviten, Arnon Rosenthal
  • Inhibitors of complement factors and uses thereof
    Patent number: 11814404
    Abstract: Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.
    Type: Grant
    Filed: July 19, 2021
    Date of Patent: November 14, 2023
    Assignees: ANNEXON, INC., APTUIT (VERONA) SRL
    Inventors: Dean R. Artis, Colin P. Leslie, Luca B. Mileo, Claudia Beato, Federico Sorana, Bruno Di Guglielmo, Chiara Padroni
  • Anti-complement factor C1Q antibodies and uses thereof
    Patent number: 11649279
    Abstract: The present invention provides anti-C1q antibodies and methods of using the same.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: May 16, 2023
    Assignee: Annexon, Inc.
    Inventors: Arnon Rosenthal, Michael Leviten
  • Anti-complement factor C1Q antibodies and uses thereof
    Patent number: 10927167
    Abstract: The present invention provides anti-C1q antibodies and methods of using the same.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: February 23, 2021
    Assignee: Annexon, Inc.
    Inventors: Arnon Rosenthal, Michael Leviten
  • Anti-complement factor C1q Fab fragments and uses thereof
    Patent number: 10723788
    Abstract: The present disclosure relates generally to anti-C1q antibody Fab fragments and methods of using the same.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: July 28, 2020
    Assignee: Annexon, Inc.
    Inventors: Ted Yednock, Sethu Sankaranarayanan, Michael Leviten, Arnon Rosenthal
  • Anti-complement factor C1q antibodies and uses thereof
    Patent number: 10590190
    Abstract: The present invention provides anti-C1q antibodies and methods of using the same.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: March 17, 2020
    Assignee: Annexon, Inc.
    Inventors: Arnon Rosenthal, Michael Leviten
  • Humanized anti-complement factor C1Q antibodies
    Patent number: 10316081
    Abstract: The present disclosure is directed to humanized anti-C1q antibodies and methods of using them.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: June 11, 2019
    Assignee: Annexon, Inc.
    Inventors: Arnon Rosenthal, Michael Leviten
  • Anti-complement factor C1q antibodies and uses thereof
    Patent number: 10227398
    Abstract: The present invention provides anti-C1q antibodies and methods of using the same.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: March 12, 2019
    Assignee: Annexon, Inc.
    Inventors: Arnon Rosenthal, Michael Leviten
  • Anti-complement factor C1q antibodies and uses thereof
    Patent number: 9708394
    Abstract: The present invention provides anti-C1q antibodies and methods of using the same.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: July 18, 2017
    Assignee: Annexon, Inc.
    Inventors: Arnon Rosenthal, Michael Leviten
  • ANTI-COMPLEMENT FACTOR C1Q FAB FRAGMENTS AND USES THEREOF
    Publication number: 20170152309
    Abstract: The present disclosure relates generally to anti-C1q antibody Fab fragments and methods of using the same.
    Type: Application
    Filed: November 23, 2016
    Publication date: June 1, 2017
    Applicant: Annexon, Inc.
    Inventors: Ted Yednock, Sethu Sankaranarayanan, Michael Leviten, Arnon Rosenthal